KROS
Keros Therapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$10.61-0.28%
Price as of Jul 20, 2026
KROS financials
Keros Therapeutics, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $244.1M | $3.5M | $151.0K | $0.00 |
| Cost of revenue | $1.5M | $0.00 | $0.00 | $0.00 |
| Gross profit | $242.6M | $3.5M | $151.0K | $0.00 |
| Operating expenses | $171.9M | $214.4M | $170.1M | $114.8M |
| Operating income | $70.6M | -$210.8M | -$169.9M | -$114.8M |
| Net income | $87.0M | -$187.4M | -$153.0M | -$104.7M |
| EBITDA | $93.4M | -$185.8M | -$152.2M | -$104.0M |
| Basic EPS | $2.34 | $-5.00 | $-5.20 | $-4.15 |
| Diluted EPS | $2.30 | $-5.00 | $-5.20 | $-4.15 |
| Balance sheet | ||||
| Cash & equivalents | $287.4M | $559.9M | $331.1M | $279.0M |
| Total assets | $338.0M | $615.9M | $370.0M | $306.8M |
| Total liabilities | $34.9M | $44.3M | $37.8M | $29.4M |
| Stockholders’ equity | $303.1M | $571.6M | $332.2M | $277.4M |
| Total debt | $16.9M | $18.9M | $14.4M | $13.3M |
| Net debt | -$270.5M | -$541.1M | -$316.7M | -$265.8M |
| Cash flow | ||||
| Operating cash flow | $107.5M | -$160.9M | -$124.5M | -$70.1M |
| Capital expenditure | -$1.6M | -$1.9M | -$2.5M | -$1.2M |
| Free cash flow | $106.0M | -$162.8M | -$127.0M | -$71.3M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | -$375.0M | $0.00 | $0.00 | $0.00 |